BGPT: Author Review: Peng-Cheng Ma

Fuel Your Discoveries

Quick Explanation Copied

Author scientific strength (evidence-based)

The provided profile suggests substantial, high-impact contributions spanning (at least) graphene/nanomaterials and infectious-disease/virology topics, visible in highly cited papers such as graphene antibacterial activity and a nature virology paper on a bat SARS-like coronavirus using the ACE2 receptor .

Long Explanation

Peng-Cheng Ma — Scientific author review (skeptical, evidence-anchored)

Evidence here is restricted to the papers explicitly listed in your provided OpenAlex excerpt (titles + DOIs). Where the excerpt may conflate similarly named researchers, I flag uncertainty rather than assume.

1) Evidence snapshot: what the cited works indicate

Selected high-impact works present in the provided dataset

Below are the DOIs explicitly present in your prompt. These are used to infer topic breadth and likely experimental domains—not to claim authorship order or responsibility beyond what the snippet supports.

Year	Topic (from title)	Key evidentiary signal	DOI	Why it matters (strength)
2020	Convalescent plasma in severe COVID-19	Prospective enrollment + clinical endpoints claimed in abstract snippet	10.1073/pnas.2004168117	Clinical relevance; journal-level credibility. Evidence strength: moderate (clinical details not fully verifiable from excerpt).
2010	Graphene antibacterial activity	Material–bio interaction with measurable antibacterial effect	10.1021/nn101097v	Bench-materials impact indicated by citation count in excerpt. Evidence strength: moderate.
2013	ACE2 receptor usage by bat SARS-like coronavirus	Experimental virology/receptor entry relevance	10.1038/nature12711	High-impact model for zoonotic receptor engagement. Evidence strength: moderate (not enough excerpted methods/controls).
2011	Protein corona mitigates graphene oxide cytotoxicity	Mechanistic materials–cell interaction concept (protein corona)	10.1021/nn200021j	Mechanism-framing supported by title/field norms; evidence strength: moderate.
2010	Graphene-based fluorescent probe for intracellular imaging	Probe design + intracellular imaging application	10.1002/smll.201000560	Translational imaging platform; evidence strength: moderate.
2020	Inactivated vaccine safety/immunogenicity outcomes	Vaccine trial outcome framing in abstract snippet	10.1001/jama.2020.15543	High-quality clinical venue; evidence strength: moderate (trial design details not shown in excerpt).

Citations for the scientific-topic inferences in this table:

2) Visual: topic breadth across the explicitly listed DOIs

Epistemic caution: this visualization is a title-based categorization of only the papers shown in the prompt (not the full publication record). Evidence for each category stems from the cited works below.

Graphene/nanomaterials: and .
Virology/zoonosis: .
Clinical therapeutics: .
Immunology/vaccines: .
Cell imaging: .

3) Strengths suggested by the evidence

Cross-domain experimental competence: The explicitly listed works cover materials/nanomedicine and virology/vaccine clinical studies, suggesting the author can contribute to heterogeneous experimental pipelines (materials characterization/biological assays vs. infectious disease experimental designs). (Grounded in titles/DOIs cited above.)
Mechanism-aware materials framing: “Protein corona-mediated mitigation” implies an attempt to move from “material works” to “material–biology mechanism,” which is a scientific maturity marker in nanotoxicology/nanobio interfaces.
Presence in high-scrutiny venues: Nature/PNAS/JAMA/ACS Nano/Small are venues with strong editorial and methodological expectations; that doesn’t guarantee quality, but it reduces the prior probability of very low rigor work. (This is probabilistic, not proof.)

4) Critical gaps & likely blind spots (what we cannot conclude from the excerpt)

Disambiguation risk (high)

The provided OpenAlex excerpt contains multiple similarly named entities (e.g., “Cheng Peng”, “Peng‐Cheng Ma”, etc.). Without retrieving and inspecting the full author identity record and paper author lists, it is unsafe to attribute every listed DOI to the exact “Peng-Cheng Ma” in question.

What would change my confidence: cross-checking ORCID(s) and verifying that the specific “Peng‐Cheng Ma” appears in the author list of each cited DOI.

Rigor cannot be judged from titles/DOIs alone

Clinical studies require verification of: randomization/blinding, endpoint definitions, adverse event reporting, sample size and power, handling of missing data, and analysis plan. Nanomaterials work requires verification of: material characterization (size/oxidation/aggregation), dose metrics, controls, and whether protein corona behavior is measured vs. assumed.

Example: “convalescent plasma effectiveness” is sensitive to confounding such as time-from-symptom onset, baseline severity, and antibody titers; these cannot be confirmed from the excerpt alone.

Citation inflation / publication bias caveat

High citation counts can reflect field size, timing, and usefulness for later work—not necessarily reproducibility or mechanistic truth. Without full-text method inspection and replication attempts, any “quality from citations” inference remains probabilistic.

5) “How to review this author properly” checklist (BGPT-style skepticism)

Identity verification: confirm ORCID and exact author name match across each DOI’s author list.
Method extraction: for each paper, extract study design, controls, blinding/randomization (if clinical), and material characterization (if nano).
Failure-mode search: look for subsequent retractions/corrections, independent replication, and sensitivity to batch/material variability.
Mechanistic plausibility tests: for protein corona/nanotoxicology, check whether “mechanism” is directly measured (protein binding profiles) vs. inferred.

Bottom-line (confidence-labeled): Based strictly on the DOIs shown, the author’s visible work includes both nanomaterials/graphene and virology/clinical COVID-19-era investigations. Evidence for “scientific impact” is moderate (high-level venue + DOI presence), while evidence for “rigor/reproducibility” is currently weak-to-moderate because the excerpt lacks methods and results tables.

Feedback:

Updated: April 07, 2026